Quinapril | Radio Compass News

Enforcement Report - Week of December 28, 2022

28 Dec 2022 //

FDA

Lupin Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Four Lots of Quinapril

21 Dec 2022 //

FDA

Enforcement Report - Week of November 2, 2022

02 Nov 2022 //

FDA

FDA: Here’s Yet Another Blood Pressure Medication Recall For Cancer Concerns

30 Oct 2022 //

FORBES

Aurobindo Pharma’s US branch issues a recall of a generic medicine

26 Oct 2022 //

ENDPTS

Aurobindo Pharma USA, Inc. Initiates Voluntary Nationwide Recall of Two (2) Lots of Quinapril and Hydrochlorothiazide

26 Oct 2022 //

FDA

Enforcement Report - Week of May 25, 2022

25 May 2022 //

FDA

Pfizer Voluntary Nationwide Recall of Lots of ACCUPRIL

23 Apr 2022 //

FDA

Health Canada Issues Recall Pfizer Canada ULC. Accupril Tabs: Nitrosamine impurity

22 Apr 2022 //

HEALTH CANADA

Enforcement Report - Week of April 13, 2022

13 Apr 2022 //

FDA

Pfizer Voluntary Nationwide Recall of Lots of ACCURETICTM (Quinapril HCl/Hydrochlorothiazide)

23 Mar 2022 //

FDA

Pfizer Canada recalls BP drug on potential cancer-causing impurity

05 Mar 2022 //

HEALTH CANADA

Enforcement Report - Week of April 12, 2017

12 Apr 2017 //

FDA

Prinston Inc Generic Quinapril Hydrochloride Approved In US

15 Sep 2016 //

FDA

AVKARE Inc., Ongoing Class III recall of Quinapril Tablets USP, 40 mg, Rx only, 50 tablets (5 X 10) unit dose pack, Manufactured for: AvKARE, Inc., Pulaski, TN 38478, UPC 5026869115, NDC 50268-691-15 because of Subpotent Drug

11 Mar 2015 //

FDA

AVKARE Inc., Ongoing Class III recall of Quinapril Tablets USP, 5 mg, Rx only, 50 tablets (5 X 10) unit dose pack, Manufactured for: AvKARE, Inc., Pulaski, TN 38478, UPC 5026868815, NDC 50268-688-15 because of Subpotent Drug